A novel HIV vaccine approach has produced broadly neutralizing antibodies (bnAbs) in rhesus macaques, according to a study reported by Genetic Engineering News. The strategy uses a priming immunogen designed to activate naive B cells, followed by a sequence of booster shots that guide those cells through necessary maturation steps.
Researchers administered the priming immunogen to activate specific B cell precursors, then delivered a series of tailored booster immunizations. This process directed the B cells along a developmental pathway that ultimately generated bnAbs capable of neutralizing diverse HIV strains.
The study marks a step forward in the longstanding effort to create an effective HIV vaccine. Germline-targeting approaches aim to coax the immune system into producing rare, broadly protective antibodies — a feat that has proven elusive in prior attempts.
The findings are preclinical, with testing limited to non-human primates. Human clinical trials would be needed to determine if the approach produces similar results in people. No timeline for such trials was disclosed in the report.
The research was published by the team behind the vaccine strategy. It builds on earlier work exploring how to prime the immune system for broadly neutralizing antibody responses against HIV, which has infected millions globally.